Annual Revenue
$26.00 M
-$84.77 M-76.53%
31 December 2023
Summary:
Cartesian Therapeutics annual revenue is currently $26.00 million, with the most recent change of -$84.77 million (-76.53%) on 31 December 2023. During the last 3 years, it has risen by +$9.41 million (+56.68%). RNAC annual revenue is now -76.53% below its all-time high of $110.78 million, reached on 31 December 2022.RNAC Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$387.00 K
-$33.06 M-98.84%
01 September 2024
Summary:
Cartesian Therapeutics quarterly revenue is currently $387.00 thousand, with the most recent change of -$33.06 million (-98.84%) on 01 September 2024. Over the past year, it has dropped by -$6.16 million (-94.09%). RNAC quarterly revenue is now -99.01% below its all-time high of $39.27 million, reached on 01 June 2022.RNAC Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$47.94 M
-$6.16 M-11.39%
01 September 2024
Summary:
Cartesian Therapeutics TTM revenue is currently $47.94 million, with the most recent change of -$6.16 million (-11.39%) on 01 September 2024. Over the past year, it has increased by +$13.40 million (+38.82%). RNAC TTM revenue is now -62.44% below its all-time high of $127.64 million, reached on 01 June 2022.RNAC TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAC Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -76.5% | -94.1% | +38.8% |
| 3 y3 years | +56.7% | -98.4% | -28.6% |
| 5 y5 years | +2779.7% | - | - |
RNAC Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -76.5% | +56.7% | -99.0% | at low | -62.4% | +85.0% |
| 5 y | 5 years | -76.5% | +2779.7% | -99.0% | at low | -62.4% | +618.0% |
| alltime | all time | -76.5% | >+9999.0% | -99.0% | +3770.0% | -62.4% | >+9999.0% |
Cartesian Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $387.00 K(-98.8%) | $47.94 M(-11.4%) |
| June 2024 | - | $33.45 M(+472.7%) | $54.10 M(+108.8%) |
| Mar 2024 | - | $5.84 M(-29.3%) | $25.91 M(-0.4%) |
| Dec 2023 | $26.00 M(-76.5%) | $8.27 M(+26.2%) | $26.00 M(-24.7%) |
| Sept 2023 | - | $6.55 M(+24.8%) | $34.53 M(-29.1%) |
| June 2023 | - | $5.25 M(-11.6%) | $48.69 M(-41.1%) |
| Mar 2023 | - | $5.94 M(-64.6%) | $82.72 M(-25.3%) |
| Dec 2022 | $110.78 M(+30.2%) | - | - |
| Dec 2022 | - | $16.80 M(-18.9%) | $110.78 M(-10.6%) |
| Sept 2022 | - | $20.71 M(-47.3%) | $123.92 M(-2.9%) |
| June 2022 | - | $39.27 M(+15.5%) | $127.64 M(+18.2%) |
| Mar 2022 | - | $34.00 M(+13.6%) | $108.03 M(+27.0%) |
| Dec 2021 | $85.08 M(+412.6%) | $29.94 M(+22.6%) | $85.08 M(+26.8%) |
| Sept 2021 | - | $24.43 M(+24.2%) | $67.09 M(+41.8%) |
| June 2021 | - | $19.66 M(+77.9%) | $47.31 M(+71.1%) |
| Mar 2021 | - | $11.05 M(-7.5%) | $27.65 M(+66.6%) |
| Dec 2020 | $16.60 M | $11.95 M(+157.2%) | $16.60 M(+46.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $4.65 M(-30.2%) | $11.30 M(+69.2%) |
| Dec 2019 | $6.68 M(+639.4%) | $6.65 M(>+9900.0%) | $6.68 M(+621.1%) |
| June 2019 | - | $13.00 K(+30.0%) | $926.00 K(+1.4%) |
| Mar 2019 | - | $10.00 K(-98.9%) | $913.00 K(+1.1%) |
| Dec 2018 | $903.00 K(+336.2%) | $903.00 K(+5211.8%) | $903.00 K(+336.2%) |
| Dec 2017 | $207.00 K(-97.4%) | $17.00 K(-37.0%) | $207.00 K(-93.4%) |
| Sept 2017 | - | $27.00 K(+3.8%) | $3.12 M(-24.7%) |
| June 2017 | - | $26.00 K(-81.0%) | $4.14 M(-32.5%) |
| Mar 2017 | - | $137.00 K(-95.3%) | $6.13 M(-24.1%) |
| Dec 2016 | $8.08 M(+34.5%) | $2.93 M(+179.6%) | $8.08 M(+10.9%) |
| Sept 2016 | - | $1.05 M(-48.0%) | $7.29 M(-7.1%) |
| June 2016 | - | $2.02 M(-3.4%) | $7.85 M(+11.1%) |
| Mar 2016 | - | $2.09 M(-2.2%) | $7.07 M(+17.5%) |
| Dec 2015 | $6.01 M(+97.7%) | $2.13 M(+32.8%) | $6.01 M(+55.0%) |
| Sept 2015 | - | $1.61 M(+30.0%) | $3.88 M(+70.8%) |
| June 2015 | - | $1.24 M(+19.5%) | $2.27 M(+119.5%) |
| Mar 2015 | - | $1.03 M | $1.03 M |
| Dec 2014 | $3.04 M | - | - |
FAQ
- What is Cartesian Therapeutics annual revenue?
- What is the all time high annual revenue for Cartesian Therapeutics?
- What is Cartesian Therapeutics annual revenue year-on-year change?
- What is Cartesian Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Cartesian Therapeutics?
- What is Cartesian Therapeutics quarterly revenue year-on-year change?
- What is Cartesian Therapeutics TTM revenue?
- What is the all time high TTM revenue for Cartesian Therapeutics?
- What is Cartesian Therapeutics TTM revenue year-on-year change?
What is Cartesian Therapeutics annual revenue?
The current annual revenue of RNAC is $26.00 M
What is the all time high annual revenue for Cartesian Therapeutics?
Cartesian Therapeutics all-time high annual revenue is $110.78 M
What is Cartesian Therapeutics annual revenue year-on-year change?
Over the past year, RNAC annual revenue has changed by -$84.77 M (-76.53%)
What is Cartesian Therapeutics quarterly revenue?
The current quarterly revenue of RNAC is $387.00 K
What is the all time high quarterly revenue for Cartesian Therapeutics?
Cartesian Therapeutics all-time high quarterly revenue is $39.27 M
What is Cartesian Therapeutics quarterly revenue year-on-year change?
Over the past year, RNAC quarterly revenue has changed by -$6.16 M (-94.09%)
What is Cartesian Therapeutics TTM revenue?
The current TTM revenue of RNAC is $47.94 M
What is the all time high TTM revenue for Cartesian Therapeutics?
Cartesian Therapeutics all-time high TTM revenue is $127.64 M
What is Cartesian Therapeutics TTM revenue year-on-year change?
Over the past year, RNAC TTM revenue has changed by +$13.40 M (+38.82%)